Does Molina Healthcare Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Complexity Exist?

Forteo is a recombinant form of human parathyroid hormone (1-34), sold generically as teriparatide and manufactured by Eli Lilly. The FDA approved it in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis [1]. Unlike antiresorptive agents such as alendronate or zoledronic acid, teriparatide is anabolic: it stimulates osteoblast activity, increases bone mineral density (BMD) in the spine and hip, and reduces fracture incidence [2].

The price tag explains most of the coverage friction. A 28-day supply of branded Forteo carries a list price above $3,000 per month as of 2024, making it one of the most expensive outpatient osteoporosis treatments on the market [3]. Molina Healthcare, which operates Medicaid managed care plans in 18 states and ACA Marketplace plans in several states, applies specialty-tier management to drugs in this price range. That management includes prior authorization, step therapy, and quantity limits tied directly to the FDA's 24-month lifetime cap.

Teriparatide's clinical profile is compelling. The key phase 3 trial published in the New England Journal of Medicine (N=1,637 postmenopausal women) found that teriparatide 20 mcg/day reduced new vertebral fractures by 65% (relative risk 0.35; 95% CI 0.22-0.55; P<0.001) and nonvertebral fragility fractures by 53% compared with placebo over a median 21 months [4]. Those numbers drive physician demand. They also drive insurer scrutiny, because the drug works best in patients who genuinely need anabolic therapy, and payers want to confirm that threshold has been crossed before authorizing a $36,000-per-year treatment.

How Molina Healthcare Structures Its Formulary

Molina operates distinct formularies for each state Medicaid contract and each Marketplace product. Formulary placement is not uniform. Teriparatide (branded Forteo or biosimilar Bonsity) typically lands on a specialty tier, which in Medicaid plans often carries a nominal copay of $3-$8 per prescription because federal Medicaid rules cap cost sharing, while Marketplace plans may impose 20-30% coinsurance until the out-of-pocket maximum is met [5].

The Centers for Medicare and Medicaid Services (CMS) requires Medicaid managed care organizations to cover drugs in all U.S. Pharmacopeia (USP) drug categories if those drugs are included in the state Medicaid fee-for-service formulary [6]. Osteoporosis agents, including teriparatide, fall within the USP Musculoskeletal category. This means Molina cannot simply exclude Forteo from Medicaid plans in states where the state fee-for-service program covers it. However, Molina can and does manage access through utilization management tools.

Bonsity, the first FDA-approved teriparatide biosimilar (approved June 2021 by the FDA) [7], has been placed on preferred specialty tiers by several payers. If your state's Molina plan lists Bonsity as preferred over branded Forteo, a prior authorization for Forteo specifically may be denied on a non-preferred basis unless the prescriber documents medical necessity for the brand.

Prior Authorization Criteria Molina Typically Applies to Forteo

Prior authorization (PA) is the central hurdle. While exact criteria differ by state, Molina's medical policies for teriparatide across plans generally align with the American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis [8], which grade anabolic therapy as appropriate when:

1. The patient has a T-score at or below -2.5 at the lumbar spine or femoral neck, confirmed by DXA within the prior 24 months.
2. There is a documented history of one or more fragility fractures (vertebral, hip, or other low-trauma fracture).
3. The patient has tried and failed, or has a documented contraindication to, at least one bisphosphonate (most commonly alendronate 70 mg weekly for at least six consecutive months).
4. The patient does not have conditions listed in the FDA black box warning: pre-existing hypercalcemia, skeletal malignancies or metastases, Paget's disease of bone, prior external beam radiation involving the skeleton, or unexplained alkaline phosphatase elevation [1].

The AACE 2020 guidelines state directly: "Anabolic agents are recommended as initial therapy in patients with very high fracture risk (T-score at or below -3.0 with prior fracture, or multiple vertebral fractures)" [8]. Molina PA reviewers reference this language when evaluating whether step therapy can be bypassed for a patient with severe disease at baseline.

Step therapy bypass is possible but requires documentation. A patient who presents with two or more vertebral compression fractures on imaging and a T-score of -3.2 may qualify for direct anabolic therapy without a bisphosphonate trial, provided the prescriber submits the imaging reports, the DXA result, and a clinical letter explaining why antiresorptive-first therapy is inappropriate. Failure to provide this documentation is the single most common reason for initial PA denial.

What the PA Submission Needs to Include

A complete prior authorization package for Forteo through Molina should contain the following elements, each of which addresses a specific criterion in the plan's medical policy:

DXA report. The report must be dated within 24 months and must state the T-score numerically. A report that says only "osteoporosis confirmed" without a numeric T-score may not satisfy the criterion [9].

Fracture documentation. Radiology reports showing vertebral fracture (identified as compression deformity or endplate fracture), emergency department records for hip or wrist fractures, or operative reports from fracture surgery all satisfy this requirement. A clinical note stating "history of fracture" without supporting imaging or records typically does not.

Bisphosphonate trial record or contraindication letter. If the patient completed an adequate bisphosphonate trial (generally defined as six or more consecutive months at a therapeutic dose), pharmacy dispensing records or a prior PA approval for the bisphosphonate provides the needed evidence. If the patient cannot tolerate bisphosphonates due to esophageal disease, severe renal impairment (eGFR <35 mL/min/1.73m2), or bisphosphonate-related osteonecrosis of the jaw, the prescriber must document the contraindication explicitly [10].

Prescriber attestation on the 24-month limit. The FDA label for teriparatide carries a lifetime use restriction of 24 cumulative months [1]. Molina PA forms routinely ask the prescriber to confirm the patient has not previously received teriparatide or abaloparatide (Tymlos) for 24 or more cumulative months.

Diagnosis codes. Use ICD-10-CM M81.0 (age-related osteoporosis without current pathological fracture) or M80.00XA-M80.88XS (age-related or other osteoporosis with current pathological fracture) as appropriate. An incorrect or non-specific code is a common administrative reason for denial that has nothing to do with clinical merit [11].

How to Appeal a Molina Denial for Forteo

Denials happen. The appeal process under Medicaid managed care is governed by 42 CFR Part 438, which requires Molina to provide a written denial notice, a 60-day window for a standard appeal, and an expedited appeal decision within 72 hours if the standard timeframe would seriously jeopardize the member's health [12].

A successful appeal typically adds two types of evidence the initial PA lacked: a peer-reviewed publication directly applicable to the patient's presentation, and a letter from the treating physician specifically addressing the denial rationale. If Molina denied because bisphosphonate failure was not documented, the appeal letter should attach pharmacy records confirming dispensing dates. If denial was on the basis that the patient does not meet the "very high risk" threshold, the physician can cite the AACE 2020 guidelines [8] and the NEJM trial data showing 65% vertebral fracture reduction [4].

External Independent Medical Review (IMR) is available in most states when internal appeals fail. In California, for example, the Department of Managed Health Care operates an IMR program under Health and Safety Code Section 1374.30, through which a neutral clinician reviews the denial. Approval rates through IMR vary, but patients with well-documented severe osteoporosis and prior fractures have strong clinical grounds.

The HealthRX clinical team has developed a step-by-step PA submission checklist for teriparatide coverage through Medicaid managed care plans, consolidating the documentation requirements above into a single provider-facing workflow. This framework is available to prescribers coordinating care through HealthRX.

Alternatives if Molina Denies Forteo

Denial does not mean the patient goes without anabolic therapy. Several options exist:

Abaloparatide (Tymlos). FDA-approved in April 2017 for postmenopausal osteoporosis at high fracture risk [13], abaloparatide 80 mcg/day subcutaneous injection showed a 43% reduction in new vertebral fractures vs. placebo in the ACTIVE trial (N=2,463; 18 months) [14]. Some Molina plans list Tymlos as a preferred anabolic agent, making a PA for Tymlos easier to obtain than one for Forteo in those markets.

Romosozumab (Evenity). A monoclonal antibody against sclerostin, FDA-approved in April 2019 [15], romosozumab 210 mg monthly for 12 months reduced vertebral fractures by 73% vs. placebo in the FRAME trial (N=7,180) [16]. Molina covers romosozumab in many states, though it carries a black box warning for cardiovascular events and is contraindicated within the prior 12 months of myocardial infarction or stroke.

Denosumab (Prolia). An antiresorptive RANK-L inhibitor given as 60 mg subcutaneous injection every 6 months. The FREEDOM trial (N=7,868; 36 months) found denosumab reduced hip fractures by 40% and vertebral fractures by 68% vs. placebo [17]. Prolia sits on a lower specialty tier on most Molina formularies than teriparatide and may require less onerous prior authorization.

Bisphosphonates (if not yet tried). Generic alendronate 70 mg weekly costs under $10 per month and requires no prior authorization on most Molina formularies. If the patient has not yet tried a bisphosphonate, completing a 6-to-12-month trial both satisfies future step therapy requirements and may itself reduce fracture risk meaningfully. Alendronate has Level A evidence for vertebral, hip, and nonvertebral fracture reduction [18].

Bonsity (teriparatide biosimilar). If branded Forteo is denied as non-preferred but Bonsity is preferred, a switch to the biosimilar may resolve the coverage issue with no change in clinical outcome, since the FDA determined Bonsity is therapeutically equivalent [7].

Cost Assistance Programs When Coverage Fails

Even if Molina denies Forteo and the appeal does not succeed, cost assistance programs may bridge the gap:

Lilly Cares Foundation. The Lilly Cares program provides Forteo at no charge to uninsured or underinsured patients who meet income eligibility thresholds, generally at or below 400% of the federal poverty level [3]. Applications are submitted through the prescriber's office and take approximately two to three weeks to process.

Together with Lilly. This copay assistance program reduces out-of-pocket costs for commercially insured patients (not Medicaid). Because Molina's Medicaid plans prohibit manufacturer copay cards under federal anti-kickback rules, this program applies only to Molina Marketplace (ACA) plan members, not Medicaid members [5].

State Pharmaceutical Assistance Programs (SPAPs). Several states operate SPAPs that wrap around Medicaid to cover drugs or cost sharing that Medicaid does not. Patients in New Jersey, New York, Pennsylvania, and other states with SPAPs may have a secondary coverage pathway for specialty drugs like Forteo. The National Council on Aging maintains an updated list of state programs [19].

340B pricing. Patients who receive care at federally qualified health centers (FQHCs) or other 340B-covered entities may access Forteo at substantially reduced cost through the 340B Drug Pricing Program, even without plan coverage [20].

Clinical Context: Who Actually Needs Forteo?

Not every osteoporosis diagnosis warrants teriparatide. The AACE 2020 guidelines stratify fracture risk into moderate, high, and very high categories, and anabolic-first therapy is reserved for the very high risk group [8]. A patient with a T-score of -2.6, no prior fractures, and no glucocorticoid use falls in the high-risk category where a bisphosphonate is appropriate initial therapy, and Molina's step therapy requirement is clinically aligned with best practice for that patient.

The patients for whom Forteo provides the clearest benefit beyond bisphosphonates are those with multiple vertebral fractures, very low BMD (T-score at or below -3.0), ongoing glucocorticoid use, or fracture on bisphosphonate therapy. A 2022 meta-analysis of 9 randomized controlled trials (N=4,292) confirmed that teriparatide produced significantly greater BMD gains at the lumbar spine (weighted mean difference 5.4%; 95% CI 3.9-6.9%; P<0.001) compared with bisphosphonates, supporting its preferential use in the highest-risk patients [21].

After completing 24 months of teriparatide, patients require sequential antiresorptive therapy to preserve the BMD gains achieved. The DATA-Switch trial (N=94) showed that transitioning from teriparatide to denosumab after 24 months produced continued BMD gains at the spine and hip, whereas stopping teriparatide without antiresorptive follow-up resulted in rapid bone loss [22]. Molina PA reviewers increasingly request a transition plan as part of the initial authorization submission, reflecting clinical guidelines that anabolic therapy should not be used in isolation.

State-Specific Molina Coverage Notes

Molina operates in 18 states. Coverage rules for Forteo vary at the state contract level:

California (Medi-Cal managed care). The California Department of Health Care Services Drug Policy and Medical Management Division posts its Medi-Cal formulary criteria publicly. Teriparatide is covered with PA, requiring a T-score at or below -2.5 and either a fracture or bisphosphonate failure [23].

Ohio (Medicaid managed care). Ohio Medicaid publishes its preferred drug list (PDL) through the Ohio Department of Medicaid. Teriparatide is non-preferred; the preferred anabolic agent is abaloparatide in several managed care contract cycles. A non-preferred PA requires documented clinical failure of the preferred agent [24].

Texas (STAR and CHIP). Texas Medicaid covers teriparatide through Texas Vendor Drug Program (VDP) with PA. Texas VDP criteria require T-score at or below -2.5, documented fragility fracture OR failure of two antiresorptive agents, and a prescriber who is an endocrinologist, rheumatologist, or orthopedic surgeon. Primary care prescriptions for Forteo in Texas Medicaid almost always trigger a specialty prescriber requirement [25].

Florida (Medicaid managed care). Florida Agency for Health Care Administration (AHCA) maintains a preferred drug list. Teriparatide is listed in the PDL with PA criteria requiring DXA confirmation and one failed antiresorptive agent [26].

If your state is not listed, contact Molina's Member Services at the number on your insurance card and specifically request the prior authorization criteria document for teriparatide (NDC or HCPCS code J3110 for injection administration if billed under medical rather than pharmacy benefit).

Medical vs. Pharmacy Benefit: Which Applies to Forteo?

Forteo is self-injected at home and dispensed through specialty pharmacy, so it typically processes under the pharmacy benefit. However, if a patient receives the first injection in a physician's office or infusion center, some Molina plans may process that initial dose under the medical benefit using HCPCS code J3110 (teriparatide 10 mcg injection) [27].

Medical benefit billing may carry different cost sharing and different prior authorization processes than pharmacy benefit billing. Confirming with Molina's provider services line which benefit applies to your specific patient's plan prevents unexpected denials at the pharmacy counter or post-service medical claim rejections.

Monitoring Requirements During Forteo Therapy

Coverage approval often includes quantity limits that align with monitoring expectations. Molina typically authorizes a 28-day supply at a time for specialty injectables, requiring renewal PAs every 6 months. During those renewal windows, prescribers should submit:

Serum calcium measured 4-6 weeks after initiation (teriparatide transiently raises calcium, though sustained hypercalcemia is uncommon at 20 mcg/day) [28]. A follow-up DXA at 12 months provides objective evidence of BMD response to support continued authorization. The Endocrine Society's 2019 Clinical Practice Guideline for Osteoporosis in Men recommends DXA monitoring no more frequently than every 1-2 years during anabolic therapy [29].

Urinary calcium excretion should be measured in patients with a history of urolithiasis. The FDA label notes increased urinary calcium in clinical trials, and Molina PA renewals for patients with known nephrolithiasis may require documentation that urinary calcium remains below 400 mg/24 hours [1].